Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/104317
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE DE ESTADUAL DE CAMPINASpt_BR
dc.typeArtigo de periódicopt_BR
dc.titleObesity [obesidade]pt_BR
dc.contributor.authorGeloneze B.pt_BR
dc.contributor.authorErmetice M.N.pt_BR
dc.contributor.authorGeloneze S.R.pt_BR
unicamp.authorGeloneze, B., LIMED - Laboratório de Investigação em Metabolismo e Diabetes, Universidade Estadual de Campinas - UNICAMP, Rua Camargo Paes. 251 - Jd. Guanabara, CEP 13073-350 - Campinas - SP, Brazilpt_BR
unicamp.authorErmetice, M.N., LIMED - Laboratório de Investigação em Metabolismo e Diabetes, Universidade Estadual de Campinas - UNICAMPpt_BR
unicamp.authorGeloneze, S.R., LIMED - Laboratório de Investigação em Metabolismo e Diabetes, Universidade Estadual de Campinas - UNICAMPpt_BR
dc.description.abstractObesity is an epidemic disease in many countries, including Brazil. It is a multifactor disease, which depends on the interaction between genetic, behavioral and socio-cultural factors. It is important to recognize patients on risk of developing obesity and its co-morbidities in order to define objectives and improve treatment choices. The ideal weight concept must be changed to healthy weight concept. A 5 to 10% sustained weight loss has a positive effect on obese patient's health, even if the final proposed weight was not reached. The best approach is the combination of dietetic counseling and behavior changes (including physical activity) and anti-obesity medication in selected cases. No pharmacologic treatment must be used isolated. The conventional clinical treatment frequently fails in morbidly obese patients. Bariatric surgery is a safe option on these particular cases. However, the candidate to the bariatric surgery must be followed up by a multidisciplinary assistance group, even before surgery. Treatment success depends mainly on patient motivation. As obesity is a chronic disorder, treatment should be planned on a long term basis, according to the necessity of not only lose weight but also of the maintenance of this lost weight to really prevent co-morbidities. © Copyright Moreira Jr. Editora. Todos os direitos reservados.en
dc.relation.ispartofRevista Brasileira de Medicinapt_BR
dc.date.issued2007pt_BR
dc.identifier.citationRevista Brasileira De Medicina. , v. 64, n. SPEC. ISS., p. 41 - 49, 2007.pt_BR
dc.language.isoptpt_BR
dc.description.volume64pt_BR
dc.description.issuenumberSPEC. ISS.pt_BR
dc.description.firstpage41pt_BR
dc.description.lastpage49pt_BR
dc.rightsfechadopt_BR
dc.sourceScopuspt_BR
dc.identifier.issn347264pt_BR
dc.identifier.doipt_BR
dc.identifier.urlhttp://www.scopus.com/inward/record.url?eid=2-s2.0-38949193247&partnerID=40&md5=ff284f6220dec66bda6afed4ace97a67pt_BR
dc.date.available2015-06-30T18:40:52Z
dc.date.available2015-11-26T14:31:21Z-
dc.date.accessioned2015-06-30T18:40:52Z
dc.date.accessioned2015-11-26T14:31:21Z-
dc.description.provenanceMade available in DSpace on 2015-06-30T18:40:52Z (GMT). No. of bitstreams: 1 2-s2.0-38949193247.pdf: 648087 bytes, checksum: ebee5c82516b6fcf9493b9cfba786f3d (MD5) Previous issue date: 2007en
dc.description.provenanceMade available in DSpace on 2015-11-26T14:31:21Z (GMT). No. of bitstreams: 2 2-s2.0-38949193247.pdf: 648087 bytes, checksum: ebee5c82516b6fcf9493b9cfba786f3d (MD5) 2-s2.0-38949193247.pdf.txt: 48072 bytes, checksum: ff1d005022f29a821450a34094bd01f6 (MD5) Previous issue date: 2007en
dc.identifier.urihttp://www.repositorio.unicamp.br/handle/REPOSIP/104317
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/104317-
dc.identifier.idScopus2-s2.0-38949193247pt_BR
dc.description.referenceWorld Health Organization. Obesity: Preventing and Managing the Global Epidemic. Report of a World Health Organization Consultation. Geneva: World Health Organization. 2000pt_BR
dc.description.reference256. WHO Obesity Technical Report Series, no 894Diretrizes brasileiras de Obesidade, Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica, 2007I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome metabólica. Rev Soc Brás Hipert 2004pt_BR
dc.description.reference17(04)Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Health CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999pt_BR
dc.description.reference341:1097-105Zamboni, M., Armellini, F., Milani, M.P., Evaluation of regional body fat distribution: Comparison between W/H ratio and computed tomography in obeses women (1992) J Intern Med, 232 (4), pp. 341-347pt_BR
dc.description.referenceGeloneze, B., Repetto, E.M., Geloneze, S.R., Picolo, M., Cruzes, G., Tambascia, M.A., Hypertriglyceridemic waist: A useful tool to assess insulin resistances clinical practice (2002) Diabetes, 51 (SUPPL. 2), pp. A531pt_BR
dc.description.referenceAronne, L.J., Obesity as a disease: Etiology, treatment, and management considerations for the obese patient (2002) Obes Res, 10 (SUPPL. 2), pp. 95S-96Spt_BR
dc.description.referencePi-Sunyer, F.X., A review of long-term studies evaluating efficacy of weight loss in ameliorating disorders associated with obesity (1996) Clin Ther, 18, pp. 1006-1035pt_BR
dc.description.referenceMasheb, R.M., Grilo, C.M., Weight loss expectations in patients with binge-eating disorder (2002) Obes Res, 10, pp. 309-314pt_BR
dc.description.referenceCowburn, G., Hillsdon, M., Hankey, C.R., Obesity management by life-style strategies (1997) Br Med Bull, 53, pp. 389-408pt_BR
dc.description.referenceGlenny, A.M., O'Meara, S., Melville, A., Sheldon, T.A., Wilson, C., The treatment and prevention of obesity: A systematic review of literature (1997) Int J Obes, 21, pp. 715-737pt_BR
dc.description.referencePoston, W.S., Foreyt, J.P., Successful management of the obese patient (2000) Am Fam Physician, 61, pp. 3615-3622pt_BR
dc.description.referenceWadden, T.A., Foster, G.D., Behavioral treatment of obesity (2000) Med Clin North Am, 84, pp. 441-461pt_BR
dc.description.referenceGarrow, J.S., Summerbell, C.D., Meta-analysis: Effect of exercise, with or without dieting, on the body composition of overweight subjects (1995) Eur J Clin Nutr, 49, pp. 1-10pt_BR
dc.description.referenceMiller, W.C., Koceja, D.M., Hamilton, E.J., A meta-analysis of the past 25 years of weight loss research using diet, exercise, or diet plus exercise intervention (1997) Int J Obes, 21, pp. 941-947pt_BR
dc.description.referencePoston, W.S.C., Haddock, C.K., Dill, P.L., Thayer, B., Foreyt, J.P., Lifestyle treatments in randomized clinical trials of pharmacotherapies for obesity (2001) Obes Res, 9, pp. 552-563pt_BR
dc.description.referenceAyyad, C., Andersen, T., Long-term efficacy of dietary treatment of obesity: A systematic review of studies published between 1931 and 1999 (2000) Obes Rev, 1 (2), pp. 113-119pt_BR
dc.description.referenceRivlin, R.S., Therapy of obesity with hormones (1975) N Engl J Med, 292, pp. 26-29pt_BR
dc.description.referenceBashin, S., Wallace, W., Lawrence, J.B., Lesch, M., Sudden death associated with thyroid hormone abuse (1981) Am J Med, 71, pp. 887-890pt_BR
dc.description.referenceSmith, H.J., Roche, A.H.G., Jagusch, M.F., Herdson, P.B., Cardiomyopathy associated with amphetamine administration (1976) Am Heart J, 91, pp. 792-797pt_BR
dc.description.referenceWeintraub, M., Long-term weight control study: Conclusions (1992) Clin Pharmacol Ther, 51, pp. 642-646pt_BR
dc.description.referenceAbenhaim, L., Moride, Y., Brenot, F., Appetite-suppressant drugs and the risk of primary pulmonary hypertension (1996) N Eng J Med, 335, pp. 609-616pt_BR
dc.description.referenceMark, E.J., Patalas, E.D., Chang, H.T., Evans, R.J., Kessler, S.C., Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine (1997) N Eng J Med, 337, pp. 602-606pt_BR
dc.description.referenceConnoly, H.M., Xrary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D., Schaff, H.V., Valvular heart disease associated with fenfluramine-phentermine (1997) N Eng J Med, 337, pp. 581-588pt_BR
dc.description.referenceWeissman, N.J., Tighe Jr, J.F., Gottdiener, J.S., Gwynne, J.T., An assessment of heart-valve abnormalities in obese in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo N Eng J Med, 339, pp. 713-718pt_BR
dc.description.referenceWeissman, N.J., Panza, J.A., Tighe Jr, J.F., Gwynne, J.T., Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double blind, controlled trial (2001) Ann Intern Med, 134, pp. 267-273pt_BR
dc.description.referenceKerman, W.N., Viscidly, C.M., Brass, L.M., Phenylpropanolamine and the risk of hemorrhagic stroke (2000) N Eng J Med, 343, pp. 1826-1832pt_BR
dc.description.referenceWeigle, D.S., Pharmacological therapy of obesity: Past, present, and the future (2003) J Clin Endocrinol Metab, 88, pp. 2462-2469pt_BR
dc.description.referenceSchuh, L.M., Schuster, C.R., Hopper, J.A., Mendel, C.M., Abuse liability assessment of sibutramine, a novel weight control agent (2000) Psychopharmacology, 147, pp. 339-346pt_BR
dc.description.referenceJames, W.P.T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rossner, S., Saris, W.H.M., Van Gaal, L.F., Effect of sibutramine on weight maintenance after weight loss: A randomized trial (2000) Lancet, 356, pp. 2119-2125pt_BR
dc.description.referenceHazenberg, B.P., Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients (2000) Cardiology, 94, pp. 152-158pt_BR
dc.description.referenceTambascia, M.A., Geloneze, B., Repetto, E.M., Geloneze, S.R., Picolo, M., Magro, D.O., Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double blind placebo controlled trial (2003) Diab Obes Metab, , in presspt_BR
dc.description.referenceGuerciolini, R., Radu-Rdulescu, L., Boldrin, M., Dallas, J., Moore, R., Comparative evaluation of fecal fat excretion induced by orlistat and chitosan (2001) Obes Res, 9, pp. 364-367pt_BR
dc.description.referenceRossner, S., Sjostrom, L., Noack, R., Meinders, E., Noseda, G., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity (2000) Obes Res, 8, pp. 49-61pt_BR
dc.description.referenceFiner, N., James, W.P.T., Kopelman, P.G., Lean, M.E.J., Willians, G., One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor (2000) Int J Obes, 24, pp. 306-313pt_BR
dc.description.referenceLindgarde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254pt_BR
dc.description.referenceKarhunen, L., Franssila-Kallunki, A., Rissanen, P., Valve, R., Klehmainen, M., Rissanen, A., Uusitupa, M., Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction program in obese Finns (2000) Int J Obes, 24, pp. 1567-1572pt_BR
dc.description.referenceHill, J.O., Hauptman, J., Anderson, J.W., Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-year study (1999) Am J Clin Nutr, 69, pp. 1108-1116pt_BR
dc.description.referenceHeymesfield, S.G., Segal, K.R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326pt_BR
dc.description.referenceHalpern, A., Mancini, M.C., Suplicy, H., Zanella, M.T., Repetto, G., Gross, J., Jadzinsky, M., Matos, A.G., Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients (2003) Diab Obes Metab, 5, pp. 180-188pt_BR
dc.description.referenceWadden, T.A., Berkowitz, R.I., Womble, L.G., Sarwer, D.B., Arnold, M.E., Steinberg, C.M., Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial (2000) Obes Res, 8, pp. 431-437pt_BR
dc.description.referenceVan Gaal, L.F., Rissanen, A., Scheen, A.J., Ziegler, O., Rössner, S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study (2005) Lancet, 365, pp. 1389-1397. , for the RioEurope Study Grouppt_BR
dc.description.referencePi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factorsin Overweight or Obese Patients. RIO-North America: A Randomized Controlled Trial (2006) JAMA, 295, pp. 761-775pt_BR
dc.description.referenceDesprés, J.P., Golay, A., Sjöström, L., Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia (2005) N Engl J Med, 353, pp. 2121-2134. , for the Rimonabant in Obesity-Lipids Study grouppt_BR
dc.description.referenceScheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LFpt_BR
dc.description.referenceRIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006pt_BR
dc.description.reference11:368:1660-72. Erratum in: Lancet 2006.11;368:1650Allison, D.B., Mentore, J.L., Heo, M., Antipsychotic-induced weight gain: A comprehensive research synthesis (1999) Am J Psychiatry, 156, pp. 1686-1696pt_BR
dc.description.referenceMasand, P.S., Weight gain associated with psychotropic drugs (2000) Exp Opin Pharmacother, 1, pp. 377-389pt_BR
dc.description.referenceMichelson, D., Amsterdam, J.D., Quitkin, F.M., Reimherr, F.W., Rosenbaum, J.F., Zajecka, J., Sundell, K.L., Beasley Jr., C.M., Changes in weight during a 1-year trial of fluoxetine (1999) Am J Psychiatry, 156, pp. 1170-1176pt_BR
dc.description.referenceGadde, K.M., Parker, C.B., Maner, L.G., Wagner II, H.R., Logue, E.J., Drezner, M.K., Krishnan, R.R., Bupropion for weight loss: An investigation of efficacy and tolerability in overweight and obese women (2001) Obes Res, 9, pp. 544-551pt_BR
dc.description.referenceBray, G.A., Hollander, P., Klein, S., Kushner, R., Levy, B., Fitchet, M., Perry, B.H., A 6-month randomized, placebo-controlled, dose ranging trial of topiramate for weight loss in obesity (2003) Obes Res, 11, pp. 722-733pt_BR
dc.description.referenceKorner, J., Lo, J., Freda, P.U., Wardlaw, S.L., Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia (2003) Obes Res, 11, pp. 311-312pt_BR
dc.description.referenceCincotta, A.H., Meier, A.H., Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects (1996) Diabetes Care, 19, pp. 667-670pt_BR
dc.description.referenceNam, S.Y., Kim, K.R., Cha, B.S., Song, Y.D., Lim, S.K., Lee, H.C., Huh, K.B., Low-dose growth hormone treatment combined with restriction decreases insulin resistance by reducing fat and increasing muscle mass in obese type 2 diabetic patients (2001) Int J Obes, 25, pp. 1101-1107pt_BR
dc.description.referenceToubro, S., Astrup, A., Breum, L., Quaade, F., Safety and efficacy of long-term treatment with ephedrine, caffeine and an ephedrine/caffeine mixture (1993) Int J Obes, 17 (SUPPL. 1), pp. S73-S78pt_BR
dc.description.referenceBrolin, R.E., (1996) Update: NIH consensus conference. Gastrointestinal surgery for severe obesity. Nutrition, 12, pp. 403-404pt_BR
dc.description.referenceCapella, R.F., Capella, J.F., Vertical banded gastroplasty-gastric bypass: Preliminary report (1991) Obes Surg, 1, pp. 389-393pt_BR
dc.description.referenceScopinaro, N., Ginaetta, E., Adami, G.F., Biliopancreatic diversion for obesity at eighteen years (1996) Surgery, 119, pp. 261-268pt_BR
dc.description.referenceEvans, J.D., Scott, M.H., Intragastric balloon in the treatment of patients with morbid obesity (2001) Br J Surg, 88, pp. 1245-1248pt_BR
dc.description.referenceCigaina, V., Gastric pacing as therapy for morbid obesity: Preliminary results (2002) Obes Surg, 12 (SUPPL. 1), pp. 12S-16Spt_BR
dc.description.referenceChanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005 15pt_BR
dc.description.reference293(23):2873-83Godoy-Matos A et al. Treatment of obese adolescents with sibutramine: A Randomized, double, Controlled Study. The Journal of Clinical Endocrinology and Metabolism2005pt_BR
dc.description.reference90(3):1460-1465Xanthakos, A.S., Daniels, S.R., Inge, T.H., Bariatric Surgery in adolescents: An update (2006) Adolesc Med Clin, 17 (3), pp. 589-612pt_BR
dc.description.referenceInge, T.H., Krebs, N.F., Garcia, V.F., Skelton, J.A., Guice, K.S., Strauss, R.S., Bariatric Surgery for severily overweight adolescents: Concerns and recommendations (2004) Pediatrics, 114 (1), pp. 217-223. , Reviewpt_BR
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
2-s2.0-38949193247.pdf632.9 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.